BioSpace News Archive

New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low

The effects of screens on children’s sleep have been a focus of public health concern for decades.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a complete solution improving the development of cancer diagnostic tests, allowing direct RNA and DNA detection from liquid biopsy samples such as whole blood.

Phenomic AI, a biotech using AI/ML to reveal drug targets that emerge from cell-cell interactions and drive novel antibody drug discovery for challenging diseases, today announced the official launch of the company with US$6 million seed financing.

Efforts aim to improve health outcomes for vulnerable populations; follow company’s $35 million investment to re-open stores and provide continuous pharmacy services

Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $102.00 per share,

Stryker announced today the expansion of its lateral spine portfolio with the full launch of the Niagara Lateral Access System following the completion of 600 surgeries. With the addition of Niagara, Stryker offers a comprehensive and integrated portfolio of minimally invasive lateral solutions for treating spinal deformities

CRISPR Therapeutics (Nasdaq: CRSP), today announced Professor Emmanuelle Charpentier, CRISPR Therapeutics’ co-founder, has been awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system. Professor Charpentier co-founded CRISPR Therapeutics together with Rodger Novak and Shaun Foy. She is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and

Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19 -- The U.S. Phase 2 study is 75% enrolled with data expected later this quarter -- In parallel, e nrollment advancing rapidly in the g lobal COVID-19 P hase 2/3 study with opaganib -- Global emergency use authorization applications are planned, subject t

Economic activity in the hospital subsector grew in September for the fourth consecutive month, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.